GSK’s Jemperli Plus Chemotherapy Receives the EC’s Approval as a 1L Treatment of Primary Advanced or Recurrent Endometrial Cancer
Shots:
- The EC has approved Jemperli + CT (carboplatin & paclitaxel) as a 1L treatment of primary advanced or recurrent endometrial cancer in adults eligible for systemic therapy
- Approval was based on part 1 of P-III (RUBY) study assessing Jemperli + CT followed by Jemperli vs CT + PBO followed by PBO and part 2 evaluating Jemperli + CT followed by Jemperli + niraparib vs PBO in patients (n=785) with primary advanced/recurrent endometrial cancer
- Part 1 of the trial showed a 31% reduction in death risk among full population. At 2.5yrs., 61% of patients on Jemperli were alive vs 49% on chemotherapy alone, with a 16.4mos. improvement in mOS (44.6 vs 28.2mos.)
Ref: GSK | Image: GSK
Related News:- GSK’s GSK’227 Secures the US FDA’s Breakthrough Therapy Designation for Treating Late-Line R/R Osteosarcoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com